Articolul precedent |
Articolul urmator |
333 4 |
Ultima descărcare din IBN: 2024-03-17 18:50 |
SM ISO690:2012 BALTA, Cristina, DIUG, Eugen, CIOBANU, Nicolae, GURANDA, Diana, CIOBANU, Cristina, ANTON, Mihai. Formularea nanoparticulelor pentru administrare pulmonară. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 647. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | |||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | |||||||
|
|||||||
Pag. 647-647 | |||||||
|
|||||||
Descarcă PDF | |||||||
Rezumat | |||||||
Background. Chronic lung disease includes a wide variety of persistent conditions, such as: tuberculosis, asthma, cystic fibrosis, cancer, and others. Current pharmacotherapy, although effective, does not contribute to the complete restoration of lung function. An advanced strategy would be the use of nanoparticles. Objective of the study. Study of the available literature to highlight the types of nanoparticles possible to be used in the treatment of lung diseases. Material and Methods. The main sources of information on the results of research on the types of nanoparticles as vehicles for anticancer agents, antivirals, antituberculosis agents, antibiotics, steroids and current efforts to achieve the lungoriented drug were selected. Results. Traditional pharmacotherapy used in lung diseases often faces limitations, and inadequate pharmacokinetics and insufficient release of specific drugs often lead to a poor response to treatment. To solve these problems, nanoparticles as drug carriers are highly promising, such as liposomes, micelles, polymeric nanoparticles, dendrimers, magnetic nanoparticles and others. The main determinant for the in vivo distribution of inhaled nanoparticles is the aerodynamic diameter of the nanoparticles (20- 100 nm). PEGylation of nanoparticles reduces their opsonization by immune cells and makes them able to enter the respiratory mucus. Conclusion. Magnetic nanoparticles and dendrimers are promising vehicles for specific lung treatment. |
|||||||
Cuvinte-cheie lung diseases, treatment, nanoparticles., maladii pulmonare, Tratament, nanoparticule |
|||||||
|